Literature DB >> 16768605

Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies.

Charles P France1, Robert H Weltman, Wouter Koek, Christopher M Cruź, Lance R McMahon.   

Abstract

The acute and chronic effects of ramelteon, an MT1/MT2 receptor agonist, were evaluated in rhesus monkeys (Macaca mulatta) to assess discriminative stimulus effects in comparison with traditional benzodiazepine receptor agonists and to assess physical dependence potential. Discriminative effects of ramelteon were compared with midazolam in untreated monkeys and in diazepam-dependent monkeys that discriminated flumazenil. Dependence potential of ramelteon after daily 1-year administration (and intermittent discontinuation) was evaluated with standard operant procedures. Ramelteon did not produce benzodiazepine-like discriminative stimulus effects at doses up to 10 mg/kg. Long-term treatment or its discontinuation had no significant effect on spontaneous behavior, operant behavior, body weight, motor activity, or posture. These findings suggest that ramelteon is not likely to have benzodiazepine-like abuse or dependence liability. Copyright 2006 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16768605     DOI: 10.1037/0735-7044.120.3.535

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  7 in total

1.  Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.

Authors:  Monique A J Mets; Juna M de Vries; Lieke M de Senerpont Domis; Edmund R Volkerts; Berend Olivier; Joris C Verster
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

Review 2.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

Review 3.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

4.  Critical appraisal of ramelteon in the treatment of insomnia.

Authors:  Monique Aj Mets; Kenny R van Deventer; Berend Olivier; Joris C Verster
Journal:  Nat Sci Sleep       Date:  2010-11-10

5.  Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications.

Authors:  Seithikurippu R Pandi-Perumal; D Warren Spence; Joris C Verster; Venkatramanujam Srinivasan; Gregory M Brown; Daniel P Cardinali; Rüdiger Hardeland
Journal:  J Cent Nerv Syst Dis       Date:  2011-04-12

6.  A review of ramelteon in the treatment of sleep disorders.

Authors:  David N Neubauer
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

7.  Indiplon in the treatment of sleep disorders.

Authors:  Alan Lankford
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.